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SelectGlia to the Rescue
When damage happens to neurons, glia are both the first responders and the long-term caregivers
that orchestrate the steps to recovery. Recent reports reveal signals that control glial reactions
to neuronal damage, provide insight into how these responses are turned off when the damage
is repaired, and suggest new therapeutic interventions, including bone marrow transplantion and
lithium treatment, to control the glial-neuron interface.Confocal image of cerebellum from
Mecp2 null mouse showing newly en-
grafted microglia (green) and Purkinje
cells (red). Image courtesy of J. Cronk.Cleaning Up Rett Pathology
The X-linked autism spectrum disorder Rett Syndrome is most often caused by
mutations in the MECP2 gene. Although the severe cognitive and develop-
mental phenotypes associated with the disorder are most often attributed to
the direct effects of MECP2 loss of function in neurons, new work by Derecki
et al. (2012) suggests that microglial impairment has an important role in disease
pathophysiology and points to an unexpected intervention that could mitigate
symptom severity. The key experiment is the remarkable demonstration that
the introduction of wild-type microglia reduces the severity of a number of
features of Rett pathology, including increased life span, breathing normaliza-
tion, and locomotor improvement. This was achieved via bone marrow trans-
plantation into irradiated MECP2 null hosts or via genetic manipulation resulting
in expression of wild-type MECP2 in myeloid cells in an otherwise knockout
background. The authors show that the bone-marrow-derived microglia engraft
in the brain and that the beneficial effects they confer are reliant upon their
phagocytic activity. Are the microglia preventing the worst symptoms by clean-
ing up the debris that accumulates during development, as follows normal cell
turnover in the brain, or is there another link between phagocytosis and glial-neuronal communication? Future studies will tell and may also provide insight into the specific transcriptional
changes that occur in microglia upon mutation in MECP2 that impedes their native ability to arrest Rett pathology.
Derecki, N.C., et al. (2012). Nature. Published online March 18, 2012. 10.1038/nature10907.Draper I and Draper II receptors function
antagonistically to promote and inhibit,
respectively, glial immune responses to
axon injury.Revealing Draper’s Secret Balancing Act
Glia are responsible for clearing up the toxic debris caused by neuronal injury that
if left to accumulate might activate an inflammatory immune response or lead to
the excitotoxic death of neighboring neurons. Logan et al. (2012), working in the
fruit fly, provide insight into how this process is activated or dialed down through
the differential functions of two isoforms of the engulfment receptor Draper.
These findings suggest that the canonical function for Draper in engulfment of
damaged neurons is carried out by the Draper I splice isoform. By swapping
the extracellular domain of Draper I with those of the other two isoforms, the
authors show that it is the intracellular domain, which harbors an immunoreceptor
tyrosine-based activation motif (ITAM), that mediates engulfment activity.
Surprisingly, Draper II impedes engulfment and does so by negatively regulating
Draper I through a mechanism that involves a previously unrecognized immunor-
eceptor tyrosine-based inhibitory motif (ITIM) and a preferential interaction with the tyrosine phosphatase Corkscrew.
Logan et al. provide further evidence that Draper II and Corkscrew signaling turns off the glial response after the
damaged axons have been cleared. An interesting open question is what signals control the relative abundance of
these two Draper isoforms.
Logan, M.A., et al. (2012). Nat. Neurosci. Published online March 18, 2012. 10.1038/nn.3066.Cell 149, April 13, 2012 ª2012 Elsevier Inc. 251
Longitudinal section of the sciatic nerve
of transgenic mice with enhanced Raf
kinase activity (myelin protein P0, green;
phospho-ERK, red).Raf Does Reparable Harm
Damage to peripheral nerves causes Schwann cells to enter a dedifferentiated
state in which they are able to remove debris at the injury site, guide regrowing
axons, and, when this process is completed, redifferentiate in order to carry
out their normal role in axon myelination. Napoli et al. (2012) now show in
a mouse model that the entry of Schwann cells into this dedifferentiated state
can be controlled by Raf kinase activity. Previous work has shown that signals
from the degenerating axons trigger the native dedifferentiation response. This
latest work establishes in vivo a pathway in Schwann cells through which these
signals are likely conveyed. The authors show that the specific activation of
Raf/ERK signaling in Schwann cells (using an inducible transgene) is sufficient
to trigger demyelination in the absence of neuronal damage, resulting in loss of
motor function. It also recapitulates other features of damage-induced dedif-
ferentiation, such as breakdown of the blood nerve barrier and stimulation of
the inflammatory response, identifying a central role for Schwann cells in medi-
ating this complex multicellular regenerative response. Once Raf activation ishalted, remyelination occurs, restoring normal mobility. These features, and the fact that increased ERK signaling
has previously been implicated in peripheral neuropathies, such as Charcot-Marie-Tooth and as a result of leprosy
infection, make this model a compelling tool with which to study the disease process and assess potential
interventions.
Napoli, I., et al. (2012). Neuron 73, 729–742.Greater remyelination is observed following nerve
crush in lithium-treated mice than in control mice.
Image courtesy of C. Massaad.Lithium Powers Remyelination
A new potential therapy for the treatment of peripheral nerve damage
is suggested by recent work from Makoukji et al. (2012), who show
that lithium chloride (LiCl), the common antidepressant, stimulates re-
myelination in mice following injury. Using two peripheral nerve injury
models (facial and sciatic nerve crush), they show that LiCl treatment
enhances myelin gene expression, the extent of remyelination, and,
in the case of the facial nerve injury, the speed of functional recovery
of whisker movement (8 days versus 14 days for the placebo-treated
group). A potential mechanism for this beneficial effect is examined in
Schwann cell lines, where it is shown that LiCl inhibits its well-known
target glycogen synthase kinase 3b (GSK 3b), which leads to the stabi-
lization and nuclear accumulation of b-catenin. b-catenin then enhances the expression of peripheral myelin genes
MPZ (encoding myelin protein zero) and PMP22 (encoding peripheral myelin protein 22) through its recruitment to
TCF/LEF elements in the genes’ promoters. From here, there are many possible next steps, among which the
most tantalizing may be moving toward assessing whether LiCl could enhance peripheral remyelination in human
trials.
Makoukji, J., et al. (2012). Proc. Natl. Acad. Sci. USA 109, 3973–3978.
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